难治性系统性红斑狼疮发病机制的研究进展与挑战
摘要
关键词
参考
Dario R ,Savino S ,Daniela R , et al.Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management.[J].Drugs,2023,83(2):117-134.DOI:10.1007/S40265-022-01824-X.
Huaxia Y ,Huazhen L ,Ziyue Z , et al.Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review.[J].Clinical reviews in allergy & immunology,2020,60(1):1-14.DOI:10.1007/s12016-020-08817-2.
Shmizu M ,Kaneko S ,Shimbo A , et al.Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus[J].Lupus,2025,34(5):533-536.DOI:10.1177/09612033251330094.
Wu Y ,Zhang W ,Liao Y , et al.Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management[J].Cellular & Molecular Biology Letters,2025,30(1):73-73.DOI:10.1186/S11658-025-00749-Z.
SzeMing L ,Shuji A ,Akio M , et al.A case of refractory systemic lupus erythematosus with monocytosis exhibiting somatic KRAS mutation.[J].Inflammation and regeneration,2022,42(1):10-10.DOI:10.1186/S41232-022-00195-W.
Shipa R M ,Beesley C ,McClusky D , et al.Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype.[J].bioRxiv : the preprint server for biology,2026,DOI:10.64898/2026.02.12.705402.
Mok C C .Immunotargets and Therapy for Systemic Lupus Erythematosus.[J].ImmunoTargets and therapy,2025,14605-629.DOI:10.2147/ITT.S485650.
Maeshima K, Abe T, Imada C, Ozaki T, Shibata H. Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus. Rheumatology (Oxford). 2024 Mar 1;63(3):e115-e117. DOI: 10.1093/rheumatology/kead553.
Martínez L D ,Rivas L N ,Guillen P S P .Rapid response to anifrolumab in refractory systemic lupus erythematosus.[J].Medicina clinica,2025,165(3):107007.DOI:10.1016/J.MEDCLI.2025.107007.
Tani C ,Cardelli C ,Zen M , et al.Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study.[J].The Journal of rheumatology,2024,DOI:10.3899/JRHEUM.2024-0053.
Kobayashi Y, Hanai S, Iwamoto T, Nakagomi D. Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab. Scand J Rheumatol. 2024 May;53(3):226-228. DOI: 10.1080/03009742.2024.2306053.
M L C ,Zoe W ,Philip L , et al.Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.[J].The British journal of dermatology,2023,189(2):DOI:10.1093/BJD/LJAD089.
Ostendorf L ,Burns M ,Durek P , et al.Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus[J].New England Journal of Medicine,2020,383(12):1149-1155.DOI:10.1056/NEJMoa2023325.
Sosa F B ,Monroy S C J ,Bruce N I , et al.Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and Belimumab.[J].Autoimmunity reviews,2025,24(8):103837.DOI:10.1016/J.AUTREV.2025.103837.
Andreas M ,Fabian M ,Dimitrios M , et al.Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.[J].Nature medicine,2022,28(10):2124-2132.DOI:10.1038/S41591-022-02017-5.
Matarneh A ,Matarneh B ,Salameh O , et al.Chimeric Antigen Receptor T Cell Therapy in Systemic Lupus Erythematosus: Mechanisms, Clinical Advances, and Future Directions a Comprehensive Review.[J].Clinical reviews in allergy & immunology,2025,68(1):103.DOI:10.1007/S12016-025-09114-6.
Aifen L ,Fengbiao G ,Quanren P , et al.Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus [J].Frontiers in Immunology,2021,12728190-728190.DOI:10.3389/FIMMU.2021.728190.
Daniel N ,Darshil P ,Jenell V , et al.Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy[J].Molecular Therapy - Methods & Clinical Development,2023,31101104-101104.DOI:10.1016/J.OMTM.2023.08.023.
Ding QY, Zhou Y, Luo HW, Wei YZ, Feng YF, Zhang DM, Wu L, Chen CJ, Zang YD, Zhang TT. Triptolide derivative STP1 ameliorates murine systemic lupus erythematosus via targeting Fyn kinase. Acta Pharmacol Sin. 2026 Feb 11. DOI: 10.1038/s41401-026-01753-5.
Yan W T ,Hua J L ,Jin C P , et al.Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus[J].Archivum Immunologiae et Therapiae Experimentalis,2021,69(1):7-7.DOI:10.1007/S00005-021-00603-Y.
Huang C ,Xing X ,Xiang X , et al.MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets[J].Biomedicine & Pharmacotherapy,2020,130110558-110558.DOI:10.1016/j.biopha.2020.110558.
Goss H C ,Tumizi A A ,Singh A .Refractory Lupus Nephritis in a Woman With Systemic Lupus Erythematosus on Immunosuppressive Therapy: A Case Report[J].Cureus,2025,17(11):e96309-e96309.DOI:10.7759/CUREUS.96309.
Darosa L ,Julianne K ,P V W .Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials.[J].Expert opinion on emerging drugs,2023,28(4):257-273.DOI:10.1080/14728214.2023.2273536.
Ramadhan A ,Troug A ,Yacyshyn E , et al.Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.[J].SAGE open medical case reports,2025,132050313X251350376.DOI:10.1177/2050313X251350376.
Danieli G M ,Antonelli E ,Longhi E , et al.The role of microbiota and oxidative stress axis and the impact of intravenous immunoglobulin in systemic lupus erythematosus.[J].Autoimmunity reviews,2024,23(9):103607.DOI:10.1016/J.AUTREV.2024.103607.
Refbacks
- 当前没有refback。